Anthem Biosciences Limited has informed the Exchange regarding a press release dated August 13, 2025, titled "Press Release on the Unaudited Consolidated Financial Results for the Quarter ended June 30, 2025".
ANTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anthem Biosciences reported strong Q1FY26 results with consolidated revenue from operations of ₹5,402 Mn, up 59.5% year-on-year from ₹3,386 Mn in Q1FY25. The CRDMO segment drove the growth, delivering ₹4,527 Mn in revenue, a 70.5% YoY increase, while the Specialty Ingredients segment contributed ₹875 Mn, up 19.7% YoY. EBITDA grew 52.7% YoY to ₹2,143 Mn with margins at 38%, and profit after tax surged 64.8% YoY to ₹1,358 Mn, translating to a 24% PAT margin. The company also maintains a healthy net cash position of ₹7,848 Mn as of June 30, 2025.
Strong YoY growth across revenue, profitability, and margins signals robust business momentum, particularly in the core CRDMO segment. The solid net cash balance and double-digit margins should be viewed positively by shareholders, supporting confidence in the company's growth trajectory.